Researchers at ChristianaCare’s Gene Editing Institute successfully used CRISPR-Cas9 to disable the NRF2 gene, reversing chemotherapy resistance in lung cancer. This approach could also apply to liver, esophageal and head/neck cancers. While promising, CRISPR carries risks – unintended DNA deletion…